EASL Policy Statement on the coexistence of NAFLD and ARLD (Patient Forum 2020)

EASL Studio S4E12 - NAFLD and NASH – moving beyond the liver biopsy – where are we now?Подробнее

EASL Policy Dialogues S2E9 - Preventing liver disease with policy measures: The Hepahealth II studyПодробнее

FLF LIVER Webinar Series | Part-One (Highlights from EASL 2020)Подробнее

Reducing the burden of alcohol-related liver disease (ARLD)Подробнее

Non-Alcoholic Fatty Liver Disease (NAFLD)Подробнее

EASL Congress 2023 - Explore the Cirrhosis and Complications track!Подробнее

EASL Policy Dialogues - Enhancing Treatment Adherence & Quality of life in Rare Liver DiseaseПодробнее

EASL Policy Dialogue Episode 2 - World Liver Day - 19 April 2023Подробнее

ILC 2021 Press Conference 25 June - NAFLD / NASHПодробнее

EASL Studio Policy Dialogues Ep4 - Fatty Liver Disease: The Approaching Tsunami in NCDsПодробнее

EASL Studio Policy Dialogues - Episode 2 - The liver, alcohol, and politicsПодробнее

Non-alcoholic Fatty Liver Disease (NAFLD)Подробнее

EASL Studio - Season 2, Episode 2 - Fats or carbs, who is the real villain?Подробнее

Non-Alcoholic Fatty Liver Disease (NAFLD)Подробнее

NAFLD Pharmacological therapy abstract sessionПодробнее

EASL Studio Special Episode “Promoting Liver Health: an urgent call for action at WHO”Подробнее

EASL Studio Policy Dialogues Episode 3 - Liver Cancer: The Risk of IgnoranceПодробнее

Obesity and non-alcoholic fatty liver disease (NAFLD)Подробнее